EDS Treatment: Managing Hypermobility and Pain

Ehlers-Danlos syndrome (EDS) treatment manages symptoms rather than repairing the underlying collagen defect, and for hypermobile EDS (hEDS), the most common type, the foundation is physical therapy built on joint stabilization and proprioceptive training, which the 2017 international guideline by Engelbert and colleagues places at the center of care. Pain is handled with multimodal, mostly non-opioid care such as low-dose naltrexone at 1.5 to 4.5 mg at bedtime, SNRIs, gabapentinoids and topical agents, plus bracing, pacing, and treatment of coexisting POTS and mast cell activation syndrome.

How EDS Treatment Works

There’s no pill that fixes faulty collagen. No surgery corrects the underlying genetic defect. This is the first thing patients need to understand about Ehlers-Danlos syndrome treatment: the goal is long-term management of symptoms and function, not correction of the genetic cause. But “management” doesn’t mean accepting misery. With the right approach, many EDS patients go from barely functioning to living active, meaningful lives.

The challenge is that EDS treatment requires coordination across multiple systems. You’re not treating a single joint or a single symptom. You’re managing a connective tissue disorder that touches almost every organ system. That means building a treatment plan that addresses joints, pain, fatigue, GI function, cardiovascular regulation, and mental health simultaneously [1].

The 2017 International Classification of the Ehlers-Danlos Syndromes, published by Malfait and colleagues for the International Consortium on the Ehlers-Danlos Syndromes, recognizes 13 subtypes [11]. Priorities depend on the subtype, so an accurate EDS diagnosis comes first. People with symptomatic hypermobility who do not meet hEDS criteria are diagnosed with hypermobility spectrum disorder (HSD) and follow the same treatment principles.

EDS Treatment by Type

Hypermobile EDS accounts for most diagnoses and has no known genetic marker, so it is diagnosed clinically using the 2017 criteria [12]. Classical EDS (cEDS) and vascular EDS (vEDS) are confirmed by genetic testing, and their treatment plans add priorities that hEDS does not have. The table below summarizes how the focus shifts by subtype.

Vascular EDS is managed differently from the hypermobile type. The international consensus by Byers and colleagues (2017) recommends confirming the COL3A1 variant, keeping blood pressure in the normal range, imaging the arteries by Doppler ultrasound, CT angiography or MR angiography about once a year, and carrying an individual emergency care plan, often called a vascular EDS passport [13].

Celiprolol is the best-studied drug in any EDS subtype. In the celiprolol trial in vascular EDS led by Ong and colleagues (The Lancet, 2010), 53 patients were randomized, and arterial rupture or dissection occurred in 20% of the celiprolol group versus 50% of untreated controls over roughly four years of follow-up [14]. Celiprolol is not approved by the FDA, so US patients with vEDS discuss blood pressure options with a vascular specialist.

Physical Therapy: The Cornerstone

If EDS treatment were a pyramid, physical therapy would be the base. Nothing else works as well for improving function, reducing pain, and preventing injury. But it has to be the right kind of physical therapy.

The international guideline on physical therapy for hEDS and joint hypermobility syndrome, written by Engelbert and colleagues (2017), gives physical therapy a central role in the multidisciplinary team and warns that many physical therapists are not yet familiar with hEDS [15]. The authors also say the research base is limited in size and quality, so programs rest partly on clinical consensus.

Why Standard PT Can Backfire

Most physical therapists are trained to restore range of motion after injury or surgery. Their default toolbox includes stretching, mobilization, and flexibility exercises. For an EDS patient, this approach is exactly backwards. You already have too much range of motion. Stretching hypermobile joints makes them less stable, increases pain, and raises the risk of subluxation [2].

The most common mistake is sending an EDS patient to a general PT clinic where the therapist has never worked with hypermobility. The patient gets worse, concludes that PT doesn’t work, and gives up. This isn’t a failure of physical therapy. It’s a failure of matching the right approach to the right condition.

What EDS-Informed PT Looks Like

A physical therapist experienced with EDS will focus on:

• Proprioceptive training: EDS patients have impaired proprioception, meaning their brain doesn’t accurately sense where their joints are in space. Balance exercises, unstable surface training, and joint position awareness drills help rebuild this sense. Better proprioception means fewer accidental subluxations [3].
• Joint stabilization exercises: Strengthening the muscles around unstable joints so they act as dynamic braces. The focus is on controlled, mid-range movements rather than full range of motion. Think of muscles as doing the job that loose ligaments can’t.
• Closed kinetic chain exercises: Exercises where the hand or foot is fixed (push-ups, squats, wall sits) are generally safer than open chain movements (leg extensions, bicep curls) because they distribute force across multiple joints.
• Neuromuscular re-education: Teaching muscles to fire in the correct sequence. EDS patients often develop compensatory movement patterns that overload certain joints while under-using others.
• Postural correction: Many EDS patients develop postural habits (hyperextended knees, forward head position, excessive lumbar lordosis) that increase joint stress. Retraining neutral alignment is a slow process but pays dividends long term.

Finding the Right Therapist

Look for a physical therapist who has specific experience with hypermobility disorders. Some credentials and indicators that suggest EDS familiarity:

• Fellowship training in orthopedics or sports medicine
• Experience treating performing artists, dancers, or gymnasts (populations with high hypermobility rates)
• Familiarity with the Beighton score and 2017 hEDS diagnostic criteria
• Willingness to modify standard protocols rather than applying cookie-cutter programs

The Beighton score is a 9-point screen for generalized joint hypermobility. Under the 2017 hEDS criteria, the threshold is 6 or more for prepubertal children and adolescents, 5 or more from puberty up to age 50, and 4 or more after age 50 [11].

Occupational Therapy and Joint Protection

Occupational therapy (OT) is the partner to physical therapy in EDS care: physical therapists rebuild strength and joint control, and occupational therapists change how daily tasks are done so fragile joints take less load. Keer and Simmonds (2011) describe joint protection as a core part of rehabilitation for adults with EDS [6].

An occupational therapist experienced with hypermobility typically works on:

• Hand function: Ring splints, thicker pen grips and ergonomic tools reduce finger hyperextension during writing, typing and cooking.
• Workstation and home setup: Chair height, keyboard position and screen height are adjusted to keep wrists, shoulders and neck in neutral positions.
• Energy conservation: Tasks are broken into stages, done seated where possible, and scheduled around energy levels, which supports the pacing approach described under fatigue management.
• Mobility aids: Some people with EDS use a cane, rollator, wheelchair or scooter on high-demand days. Used strategically, they protect joints and preserve energy.

Pain Management Without Opioids

Chronic pain in EDS is multifactorial: nociceptive pain from joint damage, neuropathic pain from nerve compression or sensitization, and central sensitization where the nervous system amplifies pain signals. Effective treatment usually requires addressing multiple pain mechanisms [4].

Chronic pain is close to universal in EDS. In the 2017 consortium review of EDS pain management, Chopra and colleagues cite one study in which nearly 90% of patients reported some form of chronic pain, and they list joint subluxations and dislocations, previous surgery, muscle weakness, proprioceptive disorders and vertebral instability among its causes [1]. The same review notes that treatment studies are few, so most plans combine physical therapy, one or two medications aimed at different mechanisms, braces and compression garments, and pain psychology. A wider look at chronic pain treatment options covers approaches that apply beyond EDS.

Medications That Help

• Low-dose naltrexone (LDN): Doses of 1.5 to 4.5 mg at bedtime. Works by briefly blocking opioid receptors, which triggers an upregulation of endorphin production and reduces neuroinflammation through glial cell modulation. Clinical interest in EDS pain management is growing and side effects are usually mild, but EDS-specific trials are lacking. Typically compounded by specialty pharmacies [5]. The low-dose naltrexone guide covers dosing and practical use in more detail.
• Duloxetine or milnacipran: SNRIs that work on descending pain inhibition pathways. Particularly useful when pain has a neuropathic or central sensitization component. Some patients also report less fatigue.
• Gabapentin or pregabalin: Calcium channel modulators that reduce neuropathic pain signaling. Often helpful for burning, shooting, or electrical pain qualities. Pregabalin may also improve sleep.
• Topical treatments: Compounded creams containing combinations of ketamine, gabapentin, diclofenac, or lidocaine can provide localized relief with less systemic exposure than oral medications. Lidocaine patches over painful areas are another option.
• Low-dose tricyclic antidepressants: Amitriptyline or nortriptyline at 10 to 25 mg at bedtime. Modulates pain processing, improves sleep quality, and can help with GI symptoms.

How Do EDS Pain Medications Compare?

None of these medications is FDA approved specifically for EDS, so each is used off label for EDS pain. The table sets their roles and doses beside their US regulatory status.

Why Opioids Are Problematic in EDS

Opioids aren’t categorically wrong for every EDS patient, but they’re a poor long-term strategy for several reasons:

• Tolerance develops, requiring escalating doses for the same effect
• They worsen the gastroparesis and constipation that many EDS patients already struggle with
• They contribute to fatigue and cognitive dysfunction
• They can cause opioid-induced hyperalgesia, where the medication paradoxically increases pain sensitivity
• Physical dependence complicates medication changes

For acute pain after a significant subluxation or injury, short-course NSAIDs or acetaminophen combined with rest and ice are more appropriate first-line options. Broader strategies are collected in chronic pain management without opioids.

Bracing and Orthotics

Bracing is a balancing act. Joint supports can reduce pain and prevent subluxations during high-risk activities, but wearing them all the time allows supporting muscles to weaken, making the joint more dependent on the brace [6].

General bracing principles for EDS:

• Use task-specific bracing: Wear ring splints for writing or typing. Use knee braces during prolonged walking or hiking. Use wrist supports during activities that stress the wrist. Remove them during rest.
• Soft supports over rigid braces: For most applications, compression sleeves and soft stabilizers work better than rigid braces. They provide proprioceptive input without completely immobilizing the joint.
• Custom orthotics for feet: Flat feet and ankle instability are extremely common in EDS. Custom foot orthotics can improve lower extremity alignment from the ground up, reducing knee, hip, and even lower back pain.
• Silver ring splints: For finger hyperextension and swan neck deformities. These are both functional and discreet. Several companies specialize in EDS-specific designs.

Exercise: The Right Way

Exercise is medicine for EDS, but the dose and type matter enormously. The wrong exercise program causes flares. The right one builds the muscular support system that takes load off unstable joints.

Cardiovascular Exercise

Low-impact is the key principle. Activities that minimize joint stress while building cardiovascular fitness:

• Swimming and water-based exercise: The water supports joint weight while providing resistance. Warm water (around 84 to 88°F) is especially beneficial for pain relief. Many EDS patients find aquatic therapy is where they can first exercise without pain.
• Recumbent cycling: Eliminates the gravitational challenge that worsens POTS symptoms while providing lower extremity strengthening.
• Walking: With appropriate footwear and orthotics. Start with short distances and build gradually. Use trekking poles on uneven terrain for added stability.
• Rowing: Engages large muscle groups with controlled, repetitive motion. Good for posture. Watch form carefully to avoid shoulder hyperextension at the catch.

High-impact activities (running, jumping, contact sports) generally carry too much injury risk for most EDS patients, though some with milder presentations handle them well with proper conditioning. People with vascular EDS are generally advised to avoid contact sports and heavy straining altogether because of the risk to arteries and hollow organs [13].

Strength Training Principles

Strength training is not only safe for EDS; it’s essential. But the approach needs modification [7]:

• Stay in mid-range: Avoid end-range positions where joints are most vulnerable. On bench press, stop before full lockout. On squats, don’t go past the point where you can maintain joint control.
• Slow, controlled tempo: Use a 3-1-3 tempo (3 seconds lowering, 1 second pause, 3 seconds lifting). This eliminates momentum and forces muscles to do the work instead of ligaments.
• Higher reps, moderate weight: Sets of 12 to 15 repetitions at moderate loads build muscular endurance, which is what hypermobile joints need most. Heavy singles and low-rep maximal lifts carry higher injury risk.
• Prioritize stability muscles: Rotator cuff, scapular stabilizers, core, hip abductors, and ankle stabilizers. These are the muscle groups that protect the joints most prone to EDS-related instability.
• Avoid locking out joints: Maintain a slight bend in elbows and knees during exercises. Full lockout in a hypermobile joint puts stress directly on ligaments instead of muscles.

The supporting evidence is still small: the Bathen et al. (2013) program combined physical and cognitive behavioral therapy in 12 women with hEDS, a pilot that cannot settle which exercise dose works best [7].

Managing Fatigue

Fatigue in EDS has several drivers at once. Hakim and colleagues (2017) list sleep disorders, chronic pain, deconditioning, cardiovascular autonomic dysfunction, bowel and bladder problems, psychological strain and nutritional deficiencies as common contributors, and they note there is no specific drug for EDS fatigue itself [16]. They also note that EDS overlaps with chronic fatigue syndrome, and some people diagnosed with CFS likely have unrecognized EDS.

Fatigue management in EDS requires addressing all its contributing factors simultaneously:

• Sleep hygiene and positioning: A supportive mattress, body pillow, and strategic joint support during sleep can dramatically improve sleep quality. Some patients benefit from a wedge pillow to manage GERD symptoms that disrupt sleep.
• Pacing: Activity pacing is the most effective fatigue management strategy. This means alternating periods of activity with rest before exhaustion hits, not after. Push-crash cycles (doing too much on good days, then being unable to function for days afterward) are the single biggest barrier to steady improvement.
• Treat coexisting POTS: If dysautonomia is contributing to fatigue, addressing blood volume and vascular tone (salt loading, compression garments, medications) can improve energy levels substantially. See our EDS and POTS guide for specific strategies.
• Screen for sleep disorders: EDS patients have higher rates of sleep apnea and upper airway resistance syndrome, possibly related to tissue laxity in the airway [8].

Postural orthostatic tachycardia syndrome (POTS), orthostatic hypotension and neurally mediated hypotension are all reported frequently in hEDS specialist clinics, though Hakim and colleagues (2017) note that their true prevalence has not been measured [17]. They list education, trigger avoidance, hydration and cardiovascular fitness as first steps, with medication for people whose daily function stays impaired. The POTS treatment overview and the guide to dysautonomia treatment go further into those options.

GI Management

Gastrointestinal symptoms require their own treatment track:

• Gastroparesis: Small, frequent meals. Low-fiber, low-fat foods during flares (fiber and fat slow gastric emptying). Prokinetic medications like domperidone or low-dose erythromycin if dietary changes aren’t sufficient. Domperidone is not approved in the United States and is available only through an FDA expanded access program.
• GERD: Elevate the head of the bed 6 inches. Avoid eating within 3 hours of lying down. PPI therapy if needed, though long-term use has downsides that should be discussed with your provider.
• Motility issues: A motility-focused GI specialist is worth the referral. Standard GI workups often miss the dysmotility patterns common in EDS.
• Mast cell overlap: If GI symptoms worsen with certain foods, environmental exposures, or stress, consider evaluation for mast cell activation syndrome. H1 and H2 antihistamine combinations can reduce GI inflammation driven by mast cell mediators.

Mast Cell Activation Treatment Overlap

An estimated 30 to 60% of EDS patients in some specialist cohorts also meet criteria for mast cell activation syndrome (MCAS), though estimates vary widely between studies. When present, MCAS drives a significant portion of EDS symptoms including flushing, hives, GI distress, brain fog, and pain flares. Treating MCAS can substantially improve overall EDS symptom burden, according to the review of mast cell disorders in EDS by Seneviratne, Maitland and Afrin (2017) [9].

First-line MCAS treatment typically includes:

• H1 antihistamines (cetirizine or fexofenadine, twice daily)
• H2 antihistamines (famotidine, twice daily)
• Mast cell stabilizers (cromolyn sodium, ketotifen)
• Avoiding identified triggers (which vary widely between patients)

Allergists and immunologists usually lead MCAS care. The MCAS treatment guide covers the medication steps in more depth, and the overlap of all three conditions is explained in the MCAS, POTS and EDS triad.

Psychological Support

Living with a chronic, invisible illness that took years to diagnose leaves psychological scars. Medical trauma from being dismissed or disbelieved is near-universal in the EDS community. Depression, anxiety, and grief over lost function are rational responses to a difficult situation, not signs of weakness.

Evidence-based psychological approaches for chronic illness include:

• Acceptance and Commitment Therapy (ACT): Focuses on living a valued life alongside chronic symptoms rather than waiting for symptoms to resolve before engaging in life.
• Cognitive Behavioral Therapy for chronic pain: Addresses catastrophizing, fear-avoidance behaviors, and maladaptive thought patterns that amplify suffering.
• Pain neuroscience education: Understanding how the nervous system processes pain can reduce fear and improve self-management.

A therapist experienced with chronic illness or chronic pain is essential. Generic counseling from someone unfamiliar with EDS often results in patients feeling further misunderstood.

Emerging Treatments

PRP (Platelet-Rich Plasma)

PRP injections concentrate growth factors from your own blood and inject them into damaged joints, tendons, or ligaments. The theory is that these growth factors stimulate tissue repair and reduce inflammation. For EDS patients with specific areas of joint instability or tendinopathy, PRP may offer targeted benefit. Large-scale clinical trials in EDS specifically are lacking, and results are variable [10].

The PRP study cited here, a long-term pilot by Dallaudière and colleagues (2014), treated tendinopathy in general rather than EDS [10]. PRP preparation systems are cleared by the FDA as devices, but injecting PRP for joint instability is off label and usually paid out of pocket.

Prolotherapy

Prolotherapy involves injecting a dextrose (sugar water) solution into loose ligaments or joint capsules. The mild irritation triggers an inflammatory healing response intended to tighten the tissue. Some EDS patients and their physicians report meaningful improvement in joint stability after a series of prolotherapy sessions. As with PRP, the evidence base is primarily case series and small studies rather than randomized controlled trials.

How the two injection approaches differ is laid out in prolotherapy vs PRP. For either one, set a goal before starting, such as fewer subluxations of one joint, and reassess after the first round.

Stem Cell Therapy and Exosomes

Stem cell and exosome injections are sometimes marketed to people with EDS as a way to rebuild connective tissue. No controlled trials in EDS support that claim, and the FDA has not approved any stem cell or exosome product for EDS. The stem cell therapy treatment guide covers what the evidence shows elsewhere and what to ask before paying cash.

What Doesn’t Work

Some treatments that are popular in general orthopedics are problematic for EDS:

• Repeated surgical joint tightening: Surgery to tighten lax capsules or repair ligaments has a high failure rate in EDS because the replacement tissue is made from the same faulty collagen. Some patients end up in a cycle of surgery, temporary improvement, and re-loosening.
• Aggressive manipulation (chiropractic high-velocity adjustments): Hypermobile joints don’t need more mobility. Forceful manipulation can cause subluxations or injuries, especially in the cervical spine. Gentle mobilization by a practitioner who understands EDS is different from high-velocity thrust techniques.
• Yoga (as typically taught): Standard yoga classes push into end-range flexibility, which worsens hypermobility. Modified yoga with emphasis on strength, alignment, and avoiding end-range positions can be helpful, but it needs to be taught by someone who understands EDS.

Building Your Treatment Team

Effective EDS management usually requires a coordinated team. At minimum, consider:

• A primary care provider who understands EDS (or is willing to learn)
• A physical therapist experienced with hypermobility
• A pain management specialist open to multimodal, non-opioid approaches
• A gastroenterologist if GI symptoms are significant
• A cardiologist or autonomic specialist if POTS or dysautonomia is present
• A mental health provider experienced with chronic illness

The key is communication between providers. When each specialist only sees their piece of the puzzle, treatment becomes fragmented and sometimes contradictory. Bringing copies of notes between appointments or having a care coordination document can help bridge the gaps.

Which Doctors Treat EDS?

No single specialty owns EDS. A medical geneticist confirms the subtype, and a primary care physician, rheumatologist or physiatrist usually coordinates the rest.

What EDS Treatment Costs and What Insurance Covers

The core of EDS treatment is usually covered by health insurance. Physical therapy, specialist visits, genetic testing for classical and vascular EDS, and most standard prescriptions are typically billed to insurance, although plans often limit the number of therapy visits per year or require prior authorization.

Out-of-pocket costs sit at the edges. Compounded low-dose naltrexone and topical creams are often not covered, and PRP and prolotherapy are usually cash pay because insurers treat them as investigational. Orthotics, ring splints and mobility aids may be partly covered as durable medical equipment. Ask for a written estimate before any cash-pay series.

Finding EDS-Informed Care Near You

Start with a physical therapist experienced with hypermobility and a physician who will coordinate. For the injection treatments above, the PRP clinic directory lists practices by state and city, and the PRP treatment guide explains what a typical course involves.

Listing order on Regenerated.com is not paid ranking. Featured slots are clearly labeled and capped, and a Verified label means the clinic completed credential checks rather than paying more, as set out in how Featured, Verified and organic listings work. The directory is free for patients, and inclusion in it is not an endorsement, so ask every clinic how many hypermobile patients it treats and how it adapts care for EDS.

Frequently asked questions

What is the most effective treatment for EDS?

Hypermobility-informed physical therapy is the most effective core treatment for Ehlers-Danlos syndrome, especially the hypermobile type. It focuses on joint stabilization, controlled mid-range strengthening and proprioceptive training rather than stretching. The 2017 international guideline by Engelbert and colleagues places physical therapy at the center of the care team. Most people combine it with non-opioid pain medication, task-specific bracing, activity pacing, and treatment of coexisting POTS or mast cell activation syndrome.

Can EDS go away with treatment?

EDS does not go away with treatment, because it is a lifelong genetic difference in how connective tissue is built. Treatment aims to reduce pain, prevent subluxations and restore function, and many people improve substantially with the right program. Progress usually comes from consistent EDS-informed physical therapy, pacing, sleep care and managing overlapping conditions such as POTS and MCAS, rather than from any single procedure or medication.

Should people with EDS stretch?

People with EDS should generally avoid stretching hypermobile joints, because extra range of motion makes those joints less stable and raises the risk of subluxation. Gentle stretching of genuinely tight muscles can still have a place when a therapist who understands hypermobility prescribes it. Most programs replace flexibility work with strengthening in mid-range, closed kinetic chain exercises such as wall sits, and balance training that improves joint position sense.

Does insurance cover EDS treatment?

Insurance usually covers the core of EDS treatment, including physical therapy, specialist visits, genetic testing for classical and vascular EDS, and most standard prescriptions, though visit limits and prior authorization are common. Treatments such as PRP, prolotherapy and compounded low-dose naltrexone are often paid out of pocket. Ask for written estimates before starting any cash-pay series, and ask your clinician to document medical necessity for braces and orthotics.

Is PRP or prolotherapy worth trying for EDS?

PRP and prolotherapy are reasonable to discuss for one specific unstable joint or tendon that has not improved with physical therapy, but the evidence in EDS is limited to case series and small studies. Both are usually cash pay and off label. Set a clear goal before starting, such as fewer subluxations of one shoulder, choose a clinician experienced with hypermobility, and keep strengthening work going alongside the injections.

Related Reading

• Ehlers-Danlos Syndrome: The Complete Guide
• EDS Symptoms: What to Watch For
• EDS and POTS: Why These Two Conditions Often Overlap
• POTS Treatment: Managing Postural Orthostatic Tachycardia Syndrome
• Chronic Fatigue Treatment: Evidence-Based Approaches

Sources

1. Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):212-219. doi:10.1002/ajmg.c.31554 ↩
2. Russek LN, Errico DM. Prevalence, injury rate and symptom frequency in generalized joint laxity and joint hypermobility syndrome in a “healthy” college population. Clin Rheumatol. 2016;35(4):1029-1039. doi:10.1007/s10067-015-2951-9 ↩
3. Scheper MC, de Vries JE, Verbunt J, Engelbert RH. Chronic pain in hypermobility syndrome and Ehlers-Danlos syndrome (hypermobility type): it is a challenge. J Pain Res. 2015;8:591-601. doi:10.2147/JPR.S64251 ↩
4. Rombaut L, Malfait F, De Paepe A, et al. Impairment and impact of pain in female patients with Ehlers-Danlos syndrome. Arthritis Rheum. 2011;63(7):1979-1987. doi:10.1002/art.30337 ↩
5. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2 ↩
6. Keer R, Simmonds J. Joint protection and physical rehabilitation of the adult with Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2011;157C(3):174-186. doi:10.1002/ajmg.c.30314 ↩
7. Bathen T, Hangmann AB, Hoff M, et al. Multidisciplinary treatment of disability in Ehlers-Danlos syndrome hypermobility type/hypermobility syndrome: a pilot study using a combination of physical and cognitive-behavioral therapy on 12 women. Am J Med Genet A. 2013;161A(12):3005-3011. doi:10.1002/ajmg.a.36060 ↩
8. Guilleminault C, Primeau M, Chiu HY, et al. Sleep-disordered breathing in Ehlers-Danlos syndrome: a genetic model of OSA. Chest. 2013;144(5):1503-1511. doi:10.1378/chest.13-0174 ↩
9. Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):226-236. doi:10.1002/ajmg.c.31555 ↩
10. Dallaudière B, Pesquer L, Meyer P, et al. Intratendinous injection of platelet-rich plasma under US guidance to treat tendinopathy: a long-term pilot study. J Vasc Interv Radiol. 2014;25(5):717-723. doi:10.1016/j.jvir.2014.01.026 ↩
11. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26. doi:10.1002/ajmg.c.31552 ↩
12. Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 2017;175(1):48-69. doi:10.1002/ajmg.c.31538 ↩
13. Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40-47. doi:10.1002/ajmg.c.31553 ↩
14. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376(9751):1476-1484. doi:10.1016/S0140-6736(10)60960-9 ↩
15. Engelbert RH, Juul-Kristensen B, Pacey V, et al. The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):158-167. doi:10.1002/ajmg.c.31545 ↩
16. Hakim A, De Wandele I, O’Callaghan C, et al. Chronic fatigue in Ehlers-Danlos syndrome: hypermobile type. Am J Med Genet C Semin Med Genet. 2017;175(1):175-180. doi:10.1002/ajmg.c.31542 ↩
17. Hakim A, O’Callaghan C, De Wandele I, et al. Cardiovascular autonomic dysfunction in Ehlers-Danlos syndrome: hypermobile type. Am J Med Genet C Semin Med Genet. 2017;175(1):168-174. doi:10.1002/ajmg.c.31543 ↩